TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36810250

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Stretching (active control group)
Number of subjects: 58
Study: 36810360

Group type: EXPERIMENTAL
Intervention: Intermittent intrapulmonary deflation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Positive expiratory pressure (PEP) therapy
Number of subjects: 20
Study: 36810437

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 36810609

Group type: EXPERIMENTAL
Intervention: App-delivered mindfulness program for anxiety for two months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 63
Study: 36810778

Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Family support through saving attitudes
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Family support through communication with guardian
Number of subjects: 702
Study: 36810788

Group type: EXPERIMENTAL
Intervention: Ustekinumab or TNF inhibitor (TNFi)
Number of subjects: 929
Study: 36810939

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine-based regimens (most common dose 3 to 3.9 mcg/kg)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine-based regimens
Number of subjects: 578
Study: 36810945

Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (≤ 7.5mg/day prednisone)
Number of subjects: 1078
Study: 36810959

Group type: EXPERIMENTAL
Intervention: Anti-VEGF/VEGFR targeting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel splice variants of VEGF
Number of subjects: 0
Study: 36810986

Group type: EXPERIMENTAL
Intervention: Laparoscopic PD catheter insertion
Number of subjects: 670

Group type: COMPARATOR
Intervention: Medical insertion technique (percutaneous and peritoneoscopic)
Number of subjects: 670
Study: 36811175

Group type: EXPERIMENTAL
Intervention: Glepaglutide (long-acting GLP-2 analog)
Number of subjects: 16
Study: 36811311

Group type: EXPERIMENTAL
Intervention: GLP-1, OXM, PYY (GOP) infusion for 4 weeks
Number of subjects: 24
Study: 36811382

Group type: EXPERIMENTAL
Intervention: WNT974 + encorafenib + cetuximab (COMBO10: 10 mg, COMBO7.5: 7.5 mg, COMBO5: 5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: WNT974 + encorafenib + cetuximab
Number of subjects: 20
Study: 36811462

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention
Number of subjects: 0
Study: 36811468

Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate diet (LCD)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Healthy low-fat diet (LFD)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Both diets (LCD and LFD)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Biomarker of carbohydrate (triglyceride/HDL cholesterol ratio)
Number of subjects: 609
Study: 36811474

Group type: EXPERIMENTAL
Intervention: 60% cellular chickpea powder (CCP) bread
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30% cellular chickpea powder (CCP) bread
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0% cellular chickpea powder (CCP) bread
Number of subjects: 20
Study: 36811476

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 109
Study: 36811520

Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36811557

Group type: EXPERIMENTAL
Intervention: cBMA augmentation
Number of subjects: 91

Group type: COMPARATOR
Intervention: aRCR alone (control)
Number of subjects: 91
Study: 36811565

Group type: EXPERIMENTAL
Intervention: More proinflammatory diet (EDIP score +0.75)
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Median EDIP score (0)
Number of subjects: 1631
Study: 36811566

Group type: EXPERIMENTAL
Intervention: Complex lifestyle intervention (infographics and face-to-face group sessions)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Infographics only (Control)
Number of subjects: 132
Study: 36811567

Group type: EXPERIMENTAL
Intervention: Periodic prolonged fasting (PF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioactive metabolites (spermidine, 1-methylnicotinamide, palmitoylethanolamide, oleoylethanolamide)
Number of subjects: 20
Study: 36811568

Group type: EXPERIMENTAL
Intervention: Synbiotic intervention formula (IF) containing Limosilactobacillus fermentum CECT5716 and galacto-oligosaccharides
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 540
Study: 36811718

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Number of subjects: 15
Study: 36811773

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied twice daily for 28 days
Number of subjects: 0
Study: 36811812

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg bid
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Pridopidine (all doses)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 36811822

Group type: EXPERIMENTAL
Intervention: Adjuvant osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance (placebo)
Number of subjects: 0
Study: 36811831

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: EDOF IOLs
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 67
Study: 36811846

Group type: EXPERIMENTAL
Intervention: Bilastine 0.6% ophthalmic solution
Number of subjects: 228

Group type: COMPARATOR
Intervention: Ketotifen 0.025%
Number of subjects: 228
Study: 36811861

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 100
Study: 36811901

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 11005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11005
Study: 36811902

Group type: EXPERIMENTAL
Intervention: EIS (OPUS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 547
Study: 36811905

Group type: EXPERIMENTAL
Intervention: Person-centered meetings with nurses
Number of subjects: 16
Study: 36811937

Group type: EXPERIMENTAL
Intervention: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home), 10-week intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home)
Number of subjects: 70
Study: 36811949

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg subcutaneously every 4 weeks for 16 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (from NOVA trial)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guselkumab (from NOVA trial)
Number of subjects: 20
Study: 36811952

Group type: EXPERIMENTAL
Intervention: Supportive Parenting App (SPA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 400
Study: 36811991

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) 500 mg administered <48 hours before surgery
Number of subjects: 23
Study: 36812121

Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise program
Number of subjects: 161

Group type: COMPARATOR
Intervention: Routine daily physical activity (control)
Number of subjects: 161
Study: 36812248

Group type: EXPERIMENTAL
Intervention: PedaleoVR (virtual reality system for pedaling exercise)
Number of subjects: 38
Study: 36812346

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 58
Study: 36812382

Group type: EXPERIMENTAL
Intervention: Data-to-care strategy with public health field services
Number of subjects: 1893

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1893
Study: 36812432

Group type: EXPERIMENTAL
Intervention: Focused ultrasound ablation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 94
Study: 36812434

Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy (AAV5 vector expressing Padua factor IX variant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factor IX prophylaxis (control)
Number of subjects: 0
Study: 36812433

Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec therapy (single infusion of 6×10^13 vg/kg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec therapy
Number of subjects: 134
Study: 36812441

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 36812571

Group type: EXPERIMENTAL
Intervention: XGBoost model derived on the European cohort
Number of subjects: 3933
Study: 36812616

Group type: EXPERIMENTAL
Intervention: Sensor-derived daily activity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sensor-derived median heart rate
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patient-reported symptom burden
Number of subjects: 68
Study: 36812663

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention for 10 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Health Promotion (HP) intervention for 10 weeks
Number of subjects: 190
Study: 36812723

Group type: EXPERIMENTAL
Intervention: AFD-specific treatment
Number of subjects: 7671

Group type: EXPERIMENTAL
Intervention: Lymphedema prevalence
Number of subjects: 7671

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 7671

Group type: COMPARATOR
Intervention: Classic phenotype
Number of subjects: 7671
Study: 36812894

Group type: EXPERIMENTAL
Intervention: Enhanced nutrition protocol (early initiation of intralipids and faster advancement of glucose infusion rate)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard PN protocol
Number of subjects: 90
Study: 36812938

Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Symptoms (PTSS) measured using the Impact of Event Scale-Revised
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Factors associated with PTSS
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Quality of life, sleep, and cognition
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 386
Study: 36812948

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sacubitril/valsartan
Number of subjects: 0
Study: 36813015

Group type: EXPERIMENTAL
Intervention: Range of motion (ROM) training started at 3 days postoperative
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) started at 3 weeks postoperative
Number of subjects: 200

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 200
Study: 36813084

Group type: EXPERIMENTAL
Intervention: W-SUDs (relational agent)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Psychoeducational control
Number of subjects: 400
Study: 36813086

Group type: COMPARATOR
Intervention: Youth-centered education and counseling (standard of care)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Electronic peer navigation (peer support via phone and automated monthly text messages)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Higher-intensity re-engagement interventions (for those with a lapse in engagement)
Number of subjects: 880
Study: 36813177

Group type: EXPERIMENTAL
Intervention: DeepTOP tool for tumor segmentation and outcome prediction using MRI
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DeepTOP tool for predicting pathological complete response to chemo/radiotherapy
Number of subjects: 99
Study: 36813284

Group type: EXPERIMENTAL
Intervention: Multifaceted antibiotic stewardship intervention
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1041
Study: 36813373

Group type: EXPERIMENTAL
Intervention: Transcatheter AVR
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Surgical AVR
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Change in stage of cardiac damage at 1 year after AVR
Number of subjects: 1974
Study: 36813375

Group type: EXPERIMENTAL
Intervention: Angiography-derived radial wall strain (RWS) analysis
Number of subjects: 751

Group type: COMPARATOR
Intervention: Physiological evaluation (control group)
Number of subjects: 751
Study: 36813380

Group type: EXPERIMENTAL
Intervention: Early rhythm control of atrial fibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36813496

Group type: EXPERIMENTAL
Intervention: TCP-25 gel (topical application on suction blister wounds)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gel (topical application on suction blister wounds)
Number of subjects: 24
Study: 36813503

Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 320 µg two times a day for 14 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study: 36813502

Group type: EXPERIMENTAL
Intervention: Surgery (gastrectomy, esophagectomy, pancreas resection or hepatectomy)
Number of subjects: 0
Study: 36813504

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 5 mg/g ear drops (Otalgan) one to two drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (oral analgesics, with/without antibiotics)
Number of subjects: 300
Study: 36813656

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily
Number of subjects: 817
Study: 36813747

Group type: EXPERIMENTAL
Intervention: SH-1028 200 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SH-1028 240 mg cohort
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SH-1028 300 mg cohort
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SH-1028
Number of subjects: 20
Study: 36813798

Group type: EXPERIMENTAL
Intervention: Nomogram predictive model based on age, Glasgow Coma Scale (GCS) at admission, and hydrocephalus caused by intraventricular hemorrhage (IVH)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS) at admission
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Hydrocephalus caused by intraventricular hemorrhage (IVH)
Number of subjects: 692
Study: 36813867

Group type: EXPERIMENTAL
Intervention: Concomitant nab-paclitaxel + gemcitabine chemotherapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sequential nab-paclitaxel + gemcitabine chemotherapy
Number of subjects: 146
Study: 36813886

Group type: EXPERIMENTAL
Intervention: Indotecan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Weekly dosing regimen of indotecan
Number of subjects: 41
Study: 36813902

Group type: EXPERIMENTAL
Intervention: Chronic Hypertension (cHTN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertensive Disorders of Pregnancy (HDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Hypertension (HTN)
Number of subjects: 0
Study: 36813985

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 60
Study: 36814010

Group type: EXPERIMENTAL
Intervention: PedsQL scores
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: OLS estimation method
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: CYPHP mapping algorithms
Number of subjects: 1735
Study: 36814062

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 2568

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 2568

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2568

Group type: EXPERIMENTAL
Intervention: tofacitinib/adalimumab
Number of subjects: 2568
Study: 36814182

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 19112

Group type: COMPARATOR
Intervention: Failed fibrinolysis
Number of subjects: 19112
Study: 36814185

Group type: EXPERIMENTAL
Intervention: Personalized screening interval based on prior f-Hb concentration (1, 2 or 3 years)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Current practice screening interval (2 years)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Personalized screening
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Uniform screening
Number of subjects: 20000
Study: 36814222

Group type: COMPARATOR
Intervention: Regorafenib 160 mg daily on days 1 to 21 of each 28-day cycle (INTEGRATE IIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regorafenib 90 mg days 1 to 21 in combination with intravenous nivolumab 240 mg days 1 and 15 each 28-day cycle (REGONIVO) (INTEGRATE IIb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (control) (INTEGRATE IIb)
Number of subjects: 0
Study: 36814246

Group type: EXPERIMENTAL
Intervention: Targeted therapies (13 EMA-approved drugs)
Number of subjects: 0
Study: 36814280

Group type: EXPERIMENTAL
Intervention: Gut microbiota diversity (Shannon index) in ICU patients
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dysbiosis index in ICU patients
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gut microbiota alterations
Number of subjects: 123
Study: 36814310

Group type: EXPERIMENTAL
Intervention: Breathe Well
Number of subjects: 40

Group type: COMPARATOR
Intervention: RPM (with in-house modification)
Number of subjects: 40
Study: 36814313

Group type: EXPERIMENTAL
Intervention: MoviS Training (12 weeks of aerobic exercise training, 2 days/week supervised and 1 day/week unsupervised, 40-70% of heart rate reserve, 20-60 min duration)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: MoviS Training (12 weeks of aerobic exercise training)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations and MoviS Training
Number of subjects: 172

Group type: COMPARATOR
Intervention: Lifestyle recommendations
Number of subjects: 172
Study: 36814438

Group type: EXPERIMENTAL
Intervention: Serum high-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Inflammatory markers (including hs-CRP, TNF-α, IL-1β, IL-6, IL-8, MCP-1)
Number of subjects: 183
Study: 36814526

Group type: EXPERIMENTAL
Intervention: Placental thickness measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Threshold placental thickness of 58mm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: History of more than three cesarean sections
Number of subjects: 40
Study: 36814594

Group type: EXPERIMENTAL
Intervention: Incentive for vaccination
Number of subjects: 406

Group type: COMPARATOR
Intervention: Cost for vaccination
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Non-monetary incentives
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 406
Study: 36814898

Group type: EXPERIMENTAL
Intervention: Serclutamab talirine (Ser-T) monotherapy at doses up to 50 μg/kg, followed by 25 μg/kg Q4W
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Serclutamab talirine (Ser-T) at recommended phase II dose (RP2D)
Number of subjects: 62
Study: 36815187

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with therapy
Number of subjects: 0
Study: 36815261

Group type: EXPERIMENTAL
Intervention: Mental health Narrative Community-Based Group Therapy (NCGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36815322

Group type: EXPERIMENTAL
Intervention: 3HP therapy (weekly rifapentine plus isoniazid)
Number of subjects: 1002
Study: 36815378

Group type: EXPERIMENTAL
Intervention: NUP98-NSD1
Number of subjects: 2235

Group type: EXPERIMENTAL
Intervention: NUP98-KDM5A
Number of subjects: 2235

Group type: EXPERIMENTAL
Intervention: NUP98-X
Number of subjects: 2235

Group type: EXPERIMENTAL
Intervention: NUP98 fusions
Number of subjects: 2235
Study: 36815464

Group type: EXPERIMENTAL
Intervention: CHW-led health coaching intervention with 4 additional group education sessions and individualized health coaching over a 6-month period
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 303
Study: 36815750

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 6
Study: 36816341

Group type: COMPARATOR
Intervention: Polypill therapy (combination of ≥2 blood pressure medications and a statin with or without aspirin)
Number of subjects: 2880

Group type: COMPARATOR
Intervention: High-risk primary prevention (age ≥40 years, hypertension, or predicted 10-year ASCVD risk ≥7.5%)
Number of subjects: 2880

Group type: COMPARATOR
Intervention: Secondary prevention (history of stroke or myocardial infarction)
Number of subjects: 2880
Study: 36816343

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, three times daily for 12 months)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 128
Study: 36816342

Group type: EXPERIMENTAL
Intervention: Vixarelimab 360 mg weekly (720 mg loading dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 36816574

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goals of 110-130 mmHg)
Number of subjects: 6501

Group type: COMPARATOR
Intervention: Standard treatment (SBP goals of 130-150 mmHg)
Number of subjects: 6501
Study: 36816939

Group type: EXPERIMENTAL
Intervention: Long-course chemoradiotherapy combined with concurrent tislelizumab (50 Gy/25 f, 2 Gy/f, 5 days/week; capecitabine 1000 mg/m2 bid, day 1-14 for three 21-day cycles; tislelizumab 200 mg, day 8 for three 21-day cycles)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Long-course chemoradiotherapy combined with concurrent tislelizumab
Number of subjects: 26
Study: 36817467

Group type: EXPERIMENTAL
Intervention: GAD-alum administered into lymph nodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD-alum injections
Number of subjects: 0
Study: 36817610

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clinician outreach
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 39
Study: 36817762

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) intervention twice a day plus standard non-pharmacological prevention measures for 5 days after surgery
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard non-pharmacological prevention measures
Number of subjects: 160